Effects of Selected Dietary Supplements on Migraine Prophylaxis: A Systematic Review and Dose-response Meta-analysis of Randomized Controlled Trials

Overview

Journal Neurol Sci

Specialty Neurology

Date 2024 Oct 15

PMID 39404918

Authors

Mahtab Karami Talandashti

Hossein Shahinfar

Pedram Delgarm

Shima Jazayeri

Affiliations

Soon will be listed here.

Abstract

Background: The existing evidence on the effect of dietary supplements for preventing migraines has generated conflicting results.

Methods: We assessed alterations in migraine clinical features corresponding to the intake of dietary supplements. Our main outcomes included the frequency (number of attacks), duration (in hours), the severity (intensity) and the monthly migraine days. Using a dose-response meta-analysis, we estimated the dose-dependent impact. The certainty of evidence was evaluated using the GRADE tool.

Results: Finally, twenty-two trials were included in the systematic review and meta-analysis. Magnesium supplementation reduced migraine attacks (mean difference (MD) = -2.51), severity (MD = -0.88), and the monthly migraine days (MD = -1.66) compared with the control group. CoQ10 decreased the frequency (MD = -1.73), severity (MD = -1.35), and duration of migraine (MD = -1.72). Riboflavin decreased attack frequency (MD = -1.34). Alpha-lipoic acid decreased attack frequency (MD = -1.24) and severity (MD = -0.38). Probiotics decreased the frequency (MD = -1.16), severity (MD = -1.07) and the monthly migraine days (MD = -3.02). Vitamin D reduced migraine frequency (MD = -1.69) and the monthly migraine days (MD = -2.41). In adults, compared with placebo, these supplements did not significantly affect other outcomes, and omega-3 supplementation did not yield a statistically significant reduction in any of these outcomes.

Conclusion: The use of certain dietary supplements has resulted in a significant decrease in migraine prophylaxis. Further clinical trials of high quality appear to be beneficial.

Citing Articles

Magnesium and Migraine.

Dominguez L, Veronese N, Sabico S, Al-Daghri N, Barbagallo M Nutrients. 2025; 17(4).

PMID: 40005053 PMC: 11858643. DOI: 10.3390/nu17040725.

References

Stovner L, Hagen K, Linde M, Steiner T . The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain. 2022; 23(1):34. PMC: 9004186. DOI: 10.1186/s10194-022-01402-2. View

Vikelis M, Spingos K, Rapoport A . A new era in headache treatment. Neurol Sci. 2018; 39(Suppl 1):47-58. DOI: 10.1007/s10072-018-3337-y. View

Castellano-Tejedor C . Non-Pharmacological Interventions for the Management of Chronic Health Conditions and Non-Communicable Diseases. Int J Environ Res Public Health. 2022; 19(14). PMC: 9317682. DOI: 10.3390/ijerph19148536. View

Puledda F, Goadsby P . An Update on Non-Pharmacological Neuromodulation for the Acute and Preventive Treatment of Migraine. Headache. 2017; 57(4):685-691. DOI: 10.1111/head.13069. View

Bianchi A, Salomone S, Caraci F, Pizza V, Bernardini R, DAmato C . Role of magnesium, coenzyme Q10, riboflavin, and vitamin B12 in migraine prophylaxis. Vitam Horm. 2004; 69:297-312. DOI: 10.1016/S0083-6729(04)69011-X. View

Sun-Edelstein C, Mauskop A . Role of magnesium in the pathogenesis and treatment of migraine. Expert Rev Neurother. 2009; 9(3):369-79. DOI: 10.1586/14737175.9.3.369. View

Chopra A, Lordan R, Horbanczuk O, Atanasov A, Chopra I, Horbanczuk J . The current use and evolving landscape of nutraceuticals. Pharmacol Res. 2021; 175:106001. DOI: 10.1016/j.phrs.2021.106001. View

Schoenen J, Jacquy J, Lenaerts M . Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology. 1998; 50(2):466-70. DOI: 10.1212/wnl.50.2.466. View

Lass A, Sohal R . Effect of coenzyme Q(10) and alpha-tocopherol content of mitochondria on the production of superoxide anion radicals. FASEB J. 2000; 14(1):87-94. DOI: 10.1096/fasebj.14.1.87. View

10.

Calder P . Dietary modification of inflammation with lipids. Proc Nutr Soc. 2002; 61(3):345-58. DOI: 10.1079/pns2002166. View

11.

Harel Z, Gascon G, Riggs S, Vaz R, Brown W, Exil G . Supplementation with omega-3 polyunsaturated fatty acids in the management of recurrent migraines in adolescents. J Adolesc Health. 2002; 31(2):154-61. DOI: 10.1016/s1054-139x(02)00349-x. View

12.

Marcotorchino J, Gouranton E, Romier B, Tourniaire F, Astier J, Malezet C . Vitamin D reduces the inflammatory response and restores glucose uptake in adipocytes. Mol Nutr Food Res. 2012; 56(12):1771-82. DOI: 10.1002/mnfr.201200383. View

13.

Pradalier A, Bakouche P, Baudesson G, Delage A, Launay J, Biason P . Failure of omega-3 polyunsaturated fatty acids in prevention of migraine: a double-blind study versus placebo. Cephalalgia. 2001; 21(8):818-22. DOI: 10.1046/j.1468-2982.2001.218240.x. View

14.

Simopoulos A . Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. 2002; 21(6):495-505. DOI: 10.1080/07315724.2002.10719248. View

16.

Mennigen R, Bruewer M . Effect of probiotics on intestinal barrier function. Ann N Y Acad Sci. 2009; 1165:183-9. DOI: 10.1111/j.1749-6632.2009.04059.x. View

17.

Chiu H, Yeh T, Huang Y, Chen P . Effects of Intravenous and Oral Magnesium on Reducing Migraine: A Meta-analysis of Randomized Controlled Trials. Pain Physician. 2016; 19(1):E97-112. View

18.

Maghsoumi-Norouzabad L, Mansoori A, Abed R, Shishehbor F . Effects of omega-3 fatty acids on the frequency, severity, and duration of migraine attacks: A systematic review and meta-analysis of randomized controlled trials. Nutr Neurosci. 2017; 21(9):614-623. DOI: 10.1080/1028415X.2017.1344371. View

19.

Parohan M, Sarraf P, Hassan Javanbakht M, Ranji-Burachaloo S, Djalali M . Effect of coenzyme Q10 supplementation on clinical features of migraine: a systematic review and dose-response meta-analysis of randomized controlled trials. Nutr Neurosci. 2019; 23(11):868-875. DOI: 10.1080/1028415X.2019.1572940. View

20.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int J Surg. 2021; 88:105906. DOI: 10.1016/j.ijsu.2021.105906. View

21.

Higgins J, Altman D, Gotzsche P, Juni P, Moher D, Oxman A . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. PMC: 3196245. DOI: 10.1136/bmj.d5928. View